Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects

Kidney International

Volumn 58, Issue 4, 2000, Pages 1420-1430

  Park, Joon Keun ^a,b,c   Müller, Dominik N ^a,b,c   Mervaala, Eero M A ^a,b,c   Dechend, Ralf ^a,b,c   Fiebeler, Anette ^a,b,c   Schmidt, Folke ^a,b,c   Bieringer, Markus ^a,b,c   Schäfer, Olaf ^a,b,c   Lindschau, Carsten ^a,b,c   Schneider, Wolfgang ^a,b,c   Ganten, Detlev ^a,b,c   Luft, Friedrich C ^a,b,c   Haller, Hermann ^a,b,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cell adhesion; Inducible nitric oxide synthase; MAP kinase; Nuclear factor B; Statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANGIOTENSIN; CERIVASTATIN; CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR AP 1; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; HYPOCHOLESTEROLEMIA; KIDNEY CORTEX NECROSIS; KIDNEY INJURY; LEUKOCYTE ADHERENCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 0033802611     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00304.x     Document Type: Article

References (48)

1. Effects of lipids on the pathogenesis of progressive renal failure: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis
2. Recent advances in statins and the kidney
3. Pharmacological treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure
4. Lovastatin retards the progression of established glomerular disease in obese Zucker rats
5. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome
6. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis
7. Are there potential non-lipid-lowering uses of statins?
8. Direct vascular effects of HMG-CoA reductase inhibitors
9. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes
10. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin
11. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions
12. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin- 1 and endothelial nitric oxide synthase in vascular endothelial cells
13. Lipids and endothelial function: Effects of lipid-lowering and other therapeutic interventions
14. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells
15. 2+ channel blocker
16. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells
17. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages
18. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: Suppression of c-Jun and c-Fos in human smooth muscle cells in vitro
19. p21ras as a common signaling target of reactive free radicals and cellular redox stress
20. High human renin hypertension in transgenic rats
21. Hypertension-induced end-organ damage: A new transgenic approach to an old problem
22. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension
23. ICAM-1 antisense oligodesoxy-nucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation
24. Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease
25. Calcineurin inhibitors inhibit angiotensin II-induced cardiac hypertrophy
26. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
27. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
28. The role of isoprenoids in vascular smooth muscle: Potential benefits of statins unrelated to cholesterol lowering
29. Blood pressure-independent effects in rats with human renin and angiotensinogen genes
30. Ischemia increases neutrophil retention and worsens acute renal failure: Role of oxygen metabolites and ICAM 1
31. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells
32. Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat
33. Macrophages in acute glomerular inflammation
34. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions
35. Statins and the kidney
36. Inhibition of nitric oxide synthase as a potential therapeutic target
37. The role of l-arginine in hypertension and nephrotoxicity
38. Nitric oxide in renal health and disease
39. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells
40. Theodore Cooper Memorial Lecture: Hypertension and the pathogenesis of atherosclerosis: Oxidative stress and the mediation of arterial inflammatory response: A new perspective
41. Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines
42. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis
43. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress
44. D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding
45. Effects of lipid-lowering agents in the Dahl salt-sensitive rat
46. Mevalonate deprivation impairs IGF-I/insulin signaling in human vascular smooth muscle cells
47. Lipids and progressive renal failure
48. Isoprenoids and Ras: Potential role in chronic rejection